Alnylam Pharmaceuticals Key Executives
This section highlights Alnylam Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Alnylam Pharmaceuticals
(Showing 0 of )
Alnylam Pharmaceuticals Earnings
This section highlights Alnylam Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-13 | $-0.62 | $0.06 |
| Read Transcript | Q3 | 2024 | 2024-10-31 | $-0.92 | $-0.50 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $-1.07 | $0.56 |
| Read Transcript | Q1 | 2024 | 2024-05-02 | $-1.12 | $-0.16 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | $-1.20 | $-1.10 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $-1.34 | $1.15 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $-1.72 | $-2.21 |
| Read Transcript | Q1 | 2023 | 2023-05-04 | $-1.97 | $-1.40 |
Financial Statements
Access annual & quarterly financial statements for Alnylam Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.25B | $1.83B | $1.04B | $844.29M | $492.85M |
| Cost of Revenue | $323.37M | $310.41M | $168.82M | $140.14M | $78.05M |
| Gross Profit | $1.92B | $1.52B | $868.60M | $704.14M | $414.80M |
| Gross Profit Ratio | 85.62% | 83.02% | 83.73% | 83.40% | 84.16% |
| Research and Development Expenses | $1.13B | $1.00B | $883.01M | $792.16M | $654.82M |
| General and Administrative Expenses | $975.53M | $795.65M | $770.66M | $620.64M | $588.42M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $975.53M | $795.65M | $770.66M | $620.64M | $588.42M |
| Other Expenses | $- | $- | $-109.37M | $-2.05M | $45.52M |
| Operating Expenses | $2.10B | $1.80B | $1.65B | $1.41B | $1.24B |
| Cost and Expenses | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B |
| Interest Income | $121.99M | $95.56M | $24.81M | $1.58M | $11.81M |
| Interest Expense | $141.86M | $121.22M | $155.97M | $143.02M | $84.50M |
| Depreciation and Amortization | $56.67M | $54.05M | $44.47M | $47.57M | $34.77M |
| EBITDA | $-178.85M | $-258.24M | $-926.56M | $-661.56M | $-736.33M |
| EBITDA Ratio | -7.95% | -14.12% | -89.31% | -78.36% | -149.40% |
| Operating Income | $-176.88M | $-282.18M | $-785.07M | $-708.65M | $-828.44M |
| Operating Income Ratio | -7.87% | -15.43% | -75.68% | -83.93% | -168.09% |
| Total Other Income Expenses Net | $-2.05M | $-151.34M | $-341.92M | $-143.49M | $-27.16M |
| Income Before Tax | $-178.94M | $-433.52M | $-1.13B | $-852.14M | $-855.60M |
| Income Before Tax Ratio | -7.96% | -23.71% | -108.63% | -100.93% | -173.60% |
| Income Tax Expense | $99.22M | $6.72M | $4.16M | $680.00K | $2.68M |
| Net Income | $-278.16M | $-440.24M | $-1.13B | $-852.82M | $-858.28M |
| Net Income Ratio | -12.37% | -24.08% | -109.04% | -101.01% | -174.15% |
| EPS | $-2.16 | $-3.52 | $-9.30 | $-7.20 | $-7.46 |
| EPS Diluted | $-2.16 | $-3.52 | $-9.30 | $-7.20 | $-7.46 |
| Weighted Average Shares Outstanding | 128.59M | 124.91M | 121.69M | 118.45M | 114.99M |
| Weighted Average Shares Outstanding Diluted | 128.59M | 124.91M | 121.69M | 118.45M | 114.99M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.17M | $500.92M | $659.83M | $494.33M | $439.72M | $750.53M | $318.75M | $319.29M | $335.04M | $264.31M | $224.82M | $213.26M | $258.54M | $187.63M | $220.55M | $177.57M | $163.56M | $125.85M | $103.96M | $99.48M |
| Cost of Revenue | $102.82M | $85.91M | $68.67M | $65.98M | $85.86M | $84.31M | $85.37M | $54.87M | $51.27M | $41.12M | $40.81M | $35.63M | $37.66M | $32.66M | $38.76M | $31.06M | $23.02M | $21.80M | $19.93M | $13.30M |
| Gross Profit | $490.35M | $415.01M | $591.15M | $428.36M | $353.86M | $666.22M | $233.38M | $264.42M | $283.77M | $223.19M | $184.01M | $177.63M | $220.87M | $154.97M | $181.80M | $146.50M | $140.54M | $104.06M | $84.03M | $86.17M |
| Gross Profit Ratio | 82.67% | 82.85% | 89.59% | 86.65% | 80.47% | 88.77% | 73.22% | 82.82% | 84.70% | 84.44% | 81.85% | 83.29% | 85.43% | 82.59% | 82.43% | 82.51% | 85.92% | 82.68% | 80.83% | 86.63% |
| Research and Development Expenses | $300.17M | $270.93M | $294.14M | $261.00M | $272.14M | $253.18M | $248.53M | $230.57M | $262.04M | $245.37M | $205.71M | $169.89M | $229.05M | $194.57M | $182.63M | $185.90M | $168.47M | $161.78M | $155.00M | $169.57M |
| General and Administrative Expenses | $295.34M | $220.99M | $248.40M | $210.80M | $198.12M | $199.18M | $214.69M | $183.66M | $210.34M | $235.86M | $169.98M | $154.47M | $186.38M | $142.07M | $145.32M | $146.86M | $166.29M | $167.47M | $127.90M | $126.76M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $295.34M | $220.99M | $248.40M | $210.80M | $198.12M | $199.18M | $214.69M | $183.66M | $210.34M | $235.86M | $169.98M | $154.47M | $186.38M | $142.07M | $145.32M | $146.86M | $166.29M | $167.47M | $127.90M | $126.76M |
| Other Expenses | $- | $- | $1.30M | $-6.04M | $1.98M | $-57.66M | $-35.42M | $-12.26M | $11.51M | $-5.12M | $-9.27M | $-6.33M | $-29.42M | $17.49M | $-140.00K | $-9.72M | $-21.95M | $-594.00K | $45.04M | $23.03M |
| Operating Expenses | $595.51M | $491.92M | $542.54M | $471.79M | $470.26M | $452.35M | $463.21M | $414.23M | $472.38M | $481.23M | $375.70M | $324.36M | $415.43M | $336.65M | $327.96M | $332.76M | $334.76M | $329.25M | $282.89M | $296.33M |
| Cost and Expenses | $698.33M | $577.82M | $611.21M | $537.77M | $556.12M | $536.66M | $548.59M | $469.10M | $523.65M | $522.35M | $416.50M | $359.99M | $453.10M | $369.31M | $366.71M | $363.82M | $357.78M | $351.05M | $302.82M | $309.63M |
| Interest Income | $31.02M | $32.15M | $29.18M | $29.64M | $30.41M | $25.43M | $21.07M | $18.66M | $14.08M | $7.82M | $1.90M | $1.01M | $495.00K | $225.00K | $409.00K | $450.00K | $1.09M | $2.07M | $3.17M | $5.48M |
| Interest Expense | $38.97M | $34.38M | $33.26M | $35.25M | $31.34M | $30.89M | $30.04M | $28.95M | $29.91M | $41.08M | $42.61M | $42.36M | $36.82M | $40.27M | $33.42M | $32.52M | $28.52M | $28.73M | $27.25M | $5.48M |
| Depreciation and Amortization | $-20.55M | $13.98M | $15.00M | $13.52M | $13.48M | $13.33M | $13.18M | $14.06M | $14.31M | $10.60M | $10.10M | $9.46M | $11.38M | $11.79M | $11.80M | $12.60M | $20.88M | $18.77M | $17.78M | $17.01M |
| EBITDA | $-154.99M | $-60.30M | $37.09M | $-14.82M | $-92.87M | $194.96M | $-231.00M | $-129.34M | $-162.80M | $-354.26M | $-221.97M | $-187.53M | $-212.11M | $-152.18M | $-143.11M | $-154.16M | $-204.70M | $-215.15M | $-142.46M | $-174.03M |
| EBITDA Ratio | -26.13% | -12.04% | 5.62% | -3.00% | -21.12% | 25.98% | -72.47% | -40.51% | -48.59% | -134.03% | -98.73% | -87.94% | -82.04% | -81.10% | -64.89% | -86.82% | -125.15% | -170.95% | -137.03% | -174.95% |
| Operating Income | $-105.16M | $-76.91M | $48.61M | $-43.44M | $-116.40M | $213.87M | $-229.83M | $-149.81M | $-188.61M | $-258.04M | $-191.69M | $-146.73M | $-194.56M | $-181.68M | $-146.16M | $-186.25M | $-194.22M | $-225.20M | $-198.86M | $-210.16M |
| Operating Income Ratio | -17.73% | -15.35% | 7.37% | -8.79% | -26.47% | 28.50% | -72.10% | -46.92% | -56.30% | -97.63% | -85.26% | -68.80% | -75.26% | -96.83% | -66.27% | -104.89% | -118.75% | -178.94% | -191.28% | -211.27% |
| Total Other Income Expenses Net | $-88.80M | $-31.76M | $-59.78M | $-20.15M | $-21.28M | $-63.13M | $-44.38M | $-22.55M | $-18.41M | $-147.90M | $-82.99M | $-92.62M | $-65.74M | $-22.56M | $-42.17M | $-13.02M | $-49.38M | $-27.25M | $20.96M | $28.51M |
| Income Before Tax | $-193.96M | $-108.66M | $-11.17M | $-63.59M | $-137.69M | $150.74M | $-274.21M | $-172.36M | $-207.02M | $-405.94M | $-274.67M | $-239.36M | $-260.30M | $-204.24M | $-188.33M | $-199.28M | $-243.60M | $-252.45M | $-177.90M | $-181.65M |
| Income Before Tax Ratio | -32.70% | -21.69% | -1.69% | -12.86% | -31.31% | 20.08% | -86.03% | -53.98% | -61.79% | -153.59% | -122.18% | -112.24% | -100.68% | -108.85% | -85.39% | -112.23% | -148.93% | -200.59% | -171.12% | -182.60% |
| Income Tax Expense | $-110.19M | $2.91M | $5.72M | $2.35M | $183.00K | $2.99M | $1.81M | $1.74M | $472.00K | $-23.00K | $2.73M | $985.00K | $-1.84M | $278.00K | $1.23M | $1.02M | $-59.00K | $839.00K | $1.33M | $575.00K |
| Net Income | $-83.76M | $-111.57M | $-16.89M | $-65.94M | $-137.87M | $147.75M | $-276.02M | $-174.10M | $-207.49M | $-405.92M | $-277.40M | $-240.34M | $-258.46M | $-204.51M | $-189.56M | $-200.29M | $-243.54M | $-253.29M | $-179.23M | $-182.22M |
| Net Income Ratio | -14.12% | -22.27% | -2.56% | -13.34% | -31.35% | 19.69% | -86.59% | -54.53% | -61.93% | -153.58% | -123.39% | -112.70% | -99.97% | -109.00% | -85.95% | -112.80% | -148.90% | -201.26% | -172.40% | -183.18% |
| EPS | $-0.65 | $-0.87 | $-0.13 | $-0.52 | $-1.10 | $1.18 | $-2.21 | $-1.40 | $-1.68 | $-3.32 | $-2.29 | $-2.00 | $-2.16 | $-1.72 | $-1.61 | $-1.71 | $-2.09 | $-2.18 | $-1.56 | $-1.62 |
| EPS Diluted | $-0.65 | $-0.87 | $-0.13 | $-0.52 | $-1.10 | $1.15 | $-2.21 | $-1.40 | $-1.68 | $-3.32 | $-2.29 | $-2.00 | $-2.16 | $-1.72 | $-1.61 | $-1.71 | $-2.09 | $-2.18 | $-1.56 | $-1.62 |
| Weighted Average Shares Outstanding | 128.59M | 128.59M | 126.73M | 126.14M | 125.61M | 125.22M | 124.66M | 124.11M | 123.27M | 122.17M | 120.90M | 120.17M | 119.77M | 118.90M | 117.77M | 117.08M | 116.27M | 115.99M | 114.91M | 112.75M |
| Weighted Average Shares Outstanding Diluted | 128.59M | 128.59M | 126.73M | 126.14M | 125.61M | 131.34M | 124.66M | 124.11M | 123.27M | 122.17M | 120.90M | 120.39M | 119.77M | 119.14M | 117.77M | 117.08M | 116.27M | 115.99M | 114.91M | 112.75M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $127.13M | $812.69M | $866.39M | $819.98M | $496.58M |
| Short Term Investments | $1.73B | $1.63B | $1.33B | $1.62B | $1.38B |
| Cash and Short Term Investments | $2.69B | $2.44B | $2.19B | $2.44B | $1.87B |
| Net Receivables | $405.31M | $327.79M | $237.96M | $198.57M | $102.41M |
| Inventory | $78.51M | $89.15M | $128.96M | $122.70M | $92.30M |
| Other Current Assets | $116.96M | $126.38M | $132.92M | $88.08M | $625.53M |
| Total Current Assets | $3.30B | $2.98B | $2.69B | $2.87B | $2.16B |
| Property Plant Equipment Net | $693.93M | $725.79M | $738.63M | $733.63M | $706.51M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $697.78M | $264.56M | $- | $- |
| Goodwill and Intangible Assets | $- | $697.78M | $264.56M | $- | $- |
| Long Term Investments | $- | $- | $-2.56B | $40.89M | $40.73M |
| Tax Assets | $116.86M | $- | $2.29B | $- | $- |
| Other Non-Current Assets | $133.90M | $-576.39M | $115.48M | $- | $500.00M |
| Total Non-Current Assets | $944.70M | $847.18M | $854.11M | $774.52M | $1.25B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B |
| Account Payables | $88.42M | $55.52M | $98.09M | $73.43M | $51.97M |
| Short Term Debt | $41.89M | $96.50M | $82.26M | $77.63M | $50.19M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $55.48M | $102.75M | $42.10M | $301.84M | $352.30M |
| Other Current Liabilities | $1.00B | $713.01M | $545.46M | $395.17M | $355.91M |
| Total Current Liabilities | $1.19B | $967.79M | $767.91M | $1.19B | $1.13B |
| Long Term Debt | $- | $2.59B | $2.53B | $2.11B | $484.32M |
| Deferred Revenue Non-Current | $- | $188.18M | $193.79M | $152.36M | $225.09M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-152.36M | $-225.09M |
| Other Non-Current Liabilities | $2.99B | $308.44M | $212.58M | $98.96M | $1.10B |
| Total Non-Current Liabilities | $2.99B | $3.08B | $2.94B | $1.86B | $1.26B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.29M | $1.26M | $1.24M | $1.20M | $1.16M |
| Retained Earnings | $- | $-7.01B | $-6.57B | $-5.44B | $-4.59B |
| Accumulated Other Comprehensive Income Loss | $- | $-23.38M | $-44.65M | $-33.26M | $-43.62M |
| Other Total Stockholders Equity | $65.80M | $6.81B | $6.45B | $6.06B | $5.64B |
| Total Stockholders Equity | $67.09M | $-220.64M | $-158.22M | $588.20M | $1.02B |
| Total Equity | $67.09M | $-220.64M | $-158.22M | $588.20M | $1.02B |
| Total Liabilities and Stockholders Equity | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B |
| Total Investments | $1.73B | $1.63B | $1.33B | $1.62B | $1.38B |
| Total Debt | $1.30B | $2.68B | $1.32B | $997.59M | $521.19M |
| Net Debt | $-127.13M | $1.87B | $453.85M | $177.62M | $24.61M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $966.43M | $1.10B | $968.49M | $681.88M | $812.69M | $1.03B | $657.80M | $672.25M | $866.39M | $1.07B | $575.56M | $534.08M | $819.98M | $1.09B | $745.77M | $379.54M | $496.58M | $496.70M | $580.83M | $467.78M |
| Short Term Investments | $1.73B | $1.67B | $1.66B | $1.69B | $1.63B | $1.37B | $1.40B | $1.40B | $1.33B | $1.19B | $1.54B | $1.71B | $1.62B | $1.23B | $1.15B | $1.33B | $1.38B | $1.34B | $1.34B | $874.42M |
| Cash and Short Term Investments | $2.69B | $2.77B | $2.62B | $2.37B | $2.44B | $2.41B | $2.06B | $2.07B | $2.19B | $2.27B | $2.11B | $2.24B | $2.44B | $2.33B | $1.90B | $1.71B | $1.87B | $1.83B | $1.93B | $1.34B |
| Net Receivables | $405.31M | $353.85M | $309.48M | $321.38M | $327.79M | $325.44M | $220.63M | $219.43M | $237.96M | $184.51M | $142.27M | $156.53M | $198.57M | $141.06M | $646.59M | $110.63M | $102.41M | $79.12M | $69.11M | $75.57M |
| Inventory | $78.51M | $75.99M | $83.98M | $93.99M | $89.15M | $95.77M | $100.45M | $131.88M | $128.96M | $115.49M | $88.98M | $78.52M | $122.70M | $97.90M | $84.36M | $73.94M | $92.30M | $66.94M | $77.42M | $68.30M |
| Other Current Assets | $116.96M | $153.67M | $154.75M | $201.96M | $126.38M | $157.96M | $145.45M | $119.03M | $132.92M | $251.03M | $129.78M | $230.13M | $88.08M | $217.07M | $94.14M | $151.96M | $625.53M | $149.53M | $88.35M | $98.70M |
| Total Current Assets | $3.30B | $3.36B | $3.17B | $2.99B | $2.98B | $2.99B | $2.52B | $2.54B | $2.69B | $2.69B | $2.47B | $2.59B | $2.87B | $2.68B | $2.73B | $1.97B | $2.16B | $2.05B | $2.16B | $1.58B |
| Property Plant Equipment Net | $693.93M | $703.40M | $715.46M | $718.93M | $725.79M | $729.08M | $736.27M | $738.08M | $738.63M | $733.62M | $732.12M | $733.16M | $733.63M | $720.79M | $708.79M | $701.78M | $706.51M | $689.92M | $668.80M | $651.09M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $697.78M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $697.78M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $52.09M | $52.23M | $51.59M | $-10.41M | $-27.26M | $-25.86M | $51.55M | $51.55M | $51.57M | $43.07M | $40.89M | $40.89M | $40.89M | $40.73M | $- | $- | $- | $- |
| Tax Assets | $116.86M | $- | $- | $- | $2.90B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $133.90M | $146.21M | $69.22M | $64.62M | $-3.53B | $134.96M | $169.33M | $138.70M | $63.93M | $59.23M | $75.09M | $67.64M | $- | $35.27M | $34.59M | $542.68M | $540.73M | $562.66M | $545.12M | $43.76M |
| Total Non-Current Assets | $944.70M | $849.62M | $836.78M | $835.78M | $847.18M | $853.62M | $878.35M | $850.92M | $854.11M | $844.41M | $858.78M | $843.87M | $774.52M | $796.95M | $784.27M | $1.29B | $1.25B | $1.25B | $1.21B | $694.85M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $4.24B | $4.21B | $4.01B | $3.82B | $3.83B | $3.84B | $3.40B | $3.39B | $3.55B | $3.54B | $3.33B | $3.43B | $3.64B | $3.47B | $3.51B | $3.26B | $3.41B | $3.31B | $3.37B | $2.28B |
| Account Payables | $88.42M | $70.81M | $73.98M | $78.15M | $55.52M | $73.84M | $59.75M | $62.24M | $98.09M | $40.57M | $52.42M | $54.92M | $73.43M | $40.05M | $53.08M | $45.38M | $51.97M | $27.87M | $26.12M | $40.48M |
| Short Term Debt | $41.89M | $42.14M | $103.62M | $87.85M | $96.50M | $41.52M | $42.07M | $43.05M | $82.26M | $41.58M | $41.24M | $41.29M | $77.63M | $40.61M | $39.36M | $38.92M | $50.19M | $32.19M | $33.45M | $58.09M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $55.48M | $71.03M | $69.01M | $76.85M | $102.75M | $77.14M | $35.38M | $35.79M | $42.10M | $144.21M | $114.29M | $131.84M | $301.84M | $115.04M | $98.14M | $116.34M | $352.30M | $114.60M | $107.59M | $86.04M |
| Other Current Liabilities | $1.00B | $1.04B | $808.64M | $698.87M | $713.01M | $757.29M | $632.18M | $532.30M | $545.46M | $546.43M | $449.74M | $377.92M | $395.17M | $414.95M | $364.06M | $294.19M | $355.91M | $305.58M | $217.14M | $154.18M |
| Total Current Liabilities | $1.19B | $1.22B | $1.06B | $941.71M | $967.79M | $949.78M | $769.38M | $673.39M | $767.91M | $772.79M | $657.68M | $605.96M | $1.19B | $610.66M | $554.65M | $494.82M | $1.13B | $480.24M | $384.30M | $338.79M |
| Long Term Debt | $1.25B | $1.26B | $2.60B | $2.60B | $2.59B | $1.27B | $1.27B | $1.28B | $1.28B | $1.28B | $949.74M | $954.10M | $2.11B | $719.83M | $721.71M | $479.61M | $484.32M | $297.26M | $281.62M | $551.56M |
| Deferred Revenue Non-Current | $- | $1.01M | $2.40M | $185.51M | $188.18M | $196.09M | $213.39M | $191.26M | $193.79M | $132.93M | $175.34M | $157.67M | $152.36M | $177.12M | $202.39M | $208.12M | $225.09M | $265.71M | $281.53M | $306.12M |
| Deferred Tax Liabilities Non-Current | $- | $- | $239.35M | $237.83M | $243.10M | $- | $- | $- | $- | $- | $- | $- | $-152.36M | $- | $- | $- | $-225.09M | $- | $- | $- |
| Other Non-Current Liabilities | $1.73B | $1.69B | $350.43M | $319.99M | $308.44M | $1.59B | $1.56B | $1.51B | $1.46B | $1.41B | $1.37B | $1.31B | $98.96M | $1.21B | $1.18B | $1.15B | $1.10B | $1.05B | $1.03B | $-266.58M |
| Total Non-Current Liabilities | $2.99B | $2.95B | $2.96B | $3.10B | $3.08B | $3.06B | $3.04B | $2.98B | $2.94B | $2.83B | $2.50B | $2.43B | $1.86B | $2.11B | $2.10B | $1.83B | $1.26B | $1.61B | $1.59B | $591.10M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- |
| Total Liabilities | $4.17B | $4.17B | $4.01B | $4.04B | $4.05B | $4.00B | $3.81B | $3.65B | $3.70B | $3.60B | $3.15B | $3.03B | $3.06B | $2.72B | $2.66B | $2.33B | $2.39B | $2.09B | $1.97B | $929.89M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.29M | $1.29M | $1.28M | $1.26M | $1.26M | $1.25M | $1.25M | $1.24M | $1.24M | $1.23M | $1.21M | $1.21M | $1.20M | $1.20M | $1.19M | $1.17M | $1.16M | $1.16M | $1.16M | $1.13M |
| Retained Earnings | $-7.29B | $-7.20B | $-7.09B | $-7.08B | $-7.01B | $-6.87B | $-7.02B | $-6.74B | $-6.57B | $-6.36B | $-5.96B | $-5.68B | $-5.44B | $-5.18B | $-4.98B | $-4.79B | $-4.59B | $-4.34B | $-4.09B | $-3.91B |
| Accumulated Other Comprehensive Income Loss | $-34.52M | $-24.83M | $-34.64M | $-26.99M | $-23.38M | $-32.34M | $-37.08M | $-39.12M | $-44.65M | $-43.78M | $-42.22M | $-38.06M | $-33.26M | $-34.23M | $-36.08M | $-36.72M | $-43.62M | $-37.19M | $-33.21M | $-32.06M |
| Other Total Stockholders Equity | $7.39B | $7.26B | $7.12B | $6.88B | $6.81B | $6.74B | $6.65B | $6.52B | $6.45B | $6.34B | $6.17B | $6.12B | $6.06B | $5.97B | $5.86B | $5.75B | $5.64B | $5.59B | $5.52B | $5.29B |
| Total Stockholders Equity | $67.09M | $32.35M | $-3.07M | $-219.27M | $-220.64M | $-165.87M | $-408.13M | $-259.24M | $-158.22M | $-67.64M | $176.04M | $401.17M | $588.20M | $755.89M | $853.36M | $926.19M | $1.02B | $1.22B | $1.40B | $1.35B |
| Total Equity | $67.09M | $32.35M | $-3.07M | $-219.27M | $-220.64M | $-165.87M | $-408.13M | $-259.24M | $-158.22M | $-67.64M | $176.04M | $401.17M | $588.20M | $755.89M | $853.36M | $926.19M | $1.02B | $1.22B | $1.40B | $1.35B |
| Total Liabilities and Stockholders Equity | $4.24B | $4.21B | $4.01B | $3.82B | $3.83B | $3.84B | $3.40B | $3.39B | $3.55B | $3.54B | $3.33B | $3.43B | $3.64B | $3.47B | $3.51B | $3.26B | $3.41B | $3.31B | $3.37B | $2.28B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $4.24B | $4.21B | $4.01B | $3.82B | $3.83B | $3.84B | $3.40B | $3.39B | $3.55B | $3.54B | $3.33B | $3.43B | $3.64B | $3.47B | $3.51B | $3.26B | $3.41B | $3.31B | $3.37B | $2.28B |
| Total Investments | $1.73B | $1.67B | $1.71B | $1.74B | $1.68B | $1.36B | $1.37B | $1.37B | $1.33B | $1.19B | $1.54B | $1.71B | $1.62B | $1.23B | $1.15B | $1.33B | $1.38B | $1.34B | $1.34B | $874.42M |
| Total Debt | $1.30B | $1.30B | $2.71B | $2.68B | $2.68B | $1.31B | $1.31B | $1.32B | $1.32B | $1.32B | $990.98M | $995.39M | $997.59M | $760.44M | $761.07M | $518.52M | $521.19M | $329.45M | $315.06M | $304.82M |
| Net Debt | $329.62M | $201.91M | $1.74B | $2.00B | $1.87B | $276.01M | $656.53M | $648.10M | $453.85M | $250.65M | $415.42M | $461.31M | $177.62M | $-333.55M | $15.30M | $138.98M | $24.61M | $-167.25M | $-265.76M | $-162.95M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-278.16M | $-440.24M | $-1.13B | $-852.82M | $-858.28M |
| Depreciation and Amortization | $56.67M | $97.03M | $85.55M | $89.69M | $74.44M |
| Deferred Income Tax | $-106.76M | $- | $- | $-55.70M | $-54.04M |
| Stock Based Compensation | $272.08M | $221.68M | $230.65M | $165.72M | $139.87M |
| Change in Working Capital | $- | $10.76M | $-35.55M | $-162.82M | $-12.70M |
| Accounts Receivables | $-86.55M | $-87.94M | $-45.60M | $-101.80M | $-56.24M |
| Inventory | $13.59M | $18.37M | $-34.14M | $-26.41M | $-35.43M |
| Accounts Payables | $91.09M | $80.84M | $191.77M | $88.24M | $117.38M |
| Other Working Capital | $- | $-509.00K | $-147.59M | $-122.85M | $-38.41M |
| Other Non Cash Items | $47.85M | $214.93M | $309.24M | $174.24M | $95.75M |
| Net Cash Provided by Operating Activities | $-8.31M | $104.16M | $-541.27M | $-641.69M | $-614.96M |
| Investments in Property Plant and Equipment | $-34.28M | $-62.21M | $-72.06M | $-76.37M | $-70.36M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-1.71B | $-1.82B | $-1.98B | $-1.66B | $-2.03B |
| Sales Maturities of Investments | $1.57B | $1.55B | $2.23B | $1.46B | $1.69B |
| Other Investing Activities | $57.76M | $-4.44M | $-13.19M | $-4.36M | $-31.20M |
| Net Cash Used for Investing Activities | $-116.84M | $-336.35M | $169.35M | $-273.30M | $-435.52M |
| Debt Repayment | $- | $- | $254.00M | $500.00M | $200.00M |
| Common Stock Issued | $- | $147.46M | $259.36M | $246.27M | $99.50M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $294.16M | $172.13M | $171.75M | $747.12M | $695.48M |
| Net Cash Used Provided by Financing Activities | $294.16M | $172.13M | $425.75M | $1.25B | $994.98M |
| Effect of Forex Changes on Cash | $-15.24M | $6.39M | $-7.43M | $-9.02M | $4.92M |
| Net Change in Cash | $153.77M | $-53.67M | $46.40M | $323.11M | $-50.58M |
| Cash at End of Period | $968.65M | $814.88M | $868.56M | $822.15M | $499.05M |
| Cash at Beginning of Period | $814.88M | $868.56M | $822.15M | $499.05M | $549.63M |
| Operating Cash Flow | $-8.31M | $104.16M | $-541.27M | $-641.69M | $-614.96M |
| Capital Expenditure | $-34.28M | $-62.21M | $-72.06M | $-76.37M | $-70.36M |
| Free Cash Flow | $-42.59M | $41.95M | $-613.33M | $-718.07M | $-685.32M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-83.76M | $-111.57M | $-16.89M | $-65.94M | $-137.87M | $147.75M | $-276.02M | $-174.10M | $-207.49M | $-405.92M | $-277.40M | $-240.34M | $-258.46M | $-204.51M | $-189.56M | $-200.29M | $-243.54M | $-253.29M | $-179.23M | $-182.22M |
| Depreciation and Amortization | $-20.55M | $48.70M | $15.00M | $13.52M | $13.48M | $23.53M | $23.45M | $26.08M | $24.89M | $20.65M | $30.55M | $9.46M | $21.45M | $23.22M | $22.16M | $22.86M | $20.88M | $18.77M | $17.78M | $17.01M |
| Deferred Income Tax | $- | $- | $- | $- | $-53.10M | $39.26M | $28.82M | $- | $- | $- | $- | $- | $5.58M | $-18.69M | $4.43M | $-47.02M | $12.58M | $3.02M | $-45.53M | $-24.11M |
| Stock Based Compensation | $91.64M | $45.80M | $89.29M | $45.35M | $41.99M | $63.94M | $75.80M | $39.95M | $42.77M | $128.12M | $30.47M | $29.29M | $44.58M | $33.37M | $32.08M | $55.69M | $34.28M | $37.26M | $33.76M | $34.58M |
| Change in Working Capital | $-74.21M | $30.73M | $-49.30M | $-121.30M | $6.79M | $25.53M | $64.58M | $-86.14M | $-13.68M | $4.65M | $33.43M | $-59.96M | $-15.11M | $-465.00K | $-21.38M | $-125.87M | $14.51M | $57.93M | $6.94M | $-92.07M |
| Accounts Receivables | $-59.51M | $-37.09M | $9.64M | $410.00K | $3.87M | $-107.99M | $-2.97M | $19.15M | $-53.27M | $-38.42M | $6.40M | $39.70M | $-59.45M | $3.67M | $-35.31M | $-10.71M | $-21.17M | $-8.97M | $6.78M | $-32.88M |
| Inventory | $849.00K | $5.92M | $6.79M | $22.00K | $11.99M | $4.79M | $1.99M | $-403.00K | $-18.98M | $-7.88M | $-9.20M | $1.93M | $-10.76M | $-13.63M | $-3.96M | $1.93M | $-8.46M | $-2.78M | $-12.23M | $-11.95M |
| Accounts Payables | $-62.11M | $83.59M | $74.47M | $-4.87M | $-38.67M | $118.74M | $82.74M | $-81.97M | $102.62M | $69.75M | $68.14M | $-48.74M | $39.50M | $46.36M | $41.82M | $-66.57M | $143.73M | $77.82M | $13.45M | $-14.21M |
| Other Working Capital | $46.55M | $-21.70M | $-140.21M | $-116.86M | $29.60M | $9.98M | $-17.18M | $-22.91M | $-44.05M | $-18.78M | $-31.91M | $-52.85M | $15.60M | $-36.87M | $-23.94M | $-50.52M | $-99.59M | $-8.13M | $-1.07M | $-33.02M |
| Other Non Cash Items | $-7.79M | $30.05M | $114.45M | $123.67M | $98.91M | $59.41M | $24.40M | $27.74M | $21.54M | $137.21M | $60.13M | $90.36M | $51.82M | $33.05M | $30.41M | $58.96M | $38.15M | $25.99M | $30.96M | $660.00K |
| Net Cash Provided by Operating Activities | $-94.66M | $43.71M | $124.16M | $-81.52M | $-29.80M | $359.41M | $-58.99M | $-166.47M | $-131.98M | $-115.28M | $-122.82M | $-171.19M | $-150.14M | $-134.04M | $-121.86M | $-235.66M | $-123.14M | $-110.33M | $-135.33M | $-246.16M |
| Investments in Property Plant and Equipment | $-9.09M | $-4.19M | $-8.02M | $-12.97M | $-15.31M | $-17.09M | $-15.92M | $-13.89M | $-21.64M | $-16.51M | $-16.05M | $-17.86M | $-21.89M | $-26.06M | $-11.25M | $-17.18M | $-21.67M | $-12.42M | $-16.66M | $-19.62M |
| Acquisitions Net | $- | $- | $- | $- | $225.35M | $-10.77M | $-7.21M | $-49.23M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-486.71M | $-449.58M | $-315.61M | $-460.09M | $-589.16M | $-421.46M | $-377.14M | $-435.75M | $-723.38M | $-157.31M | $-461.57M | $-634.71M | $-682.97M | $-458.33M | $-168.86M | $-345.95M | $-556.17M | $-329.03M | $-744.01M | $-396.41M |
| Sales Maturities of Investments | $443.01M | $423.52M | $357.57M | $405.44M | $363.81M | $432.22M | $384.35M | $373.42M | $604.72M | $492.71M | $628.92M | $505.22M | $291.45M | $396.12M | $337.30M | $438.68M | $500.95M | $331.36M | $319.74M | $539.61M |
| Other Investing Activities | $-117.00K | $- | $41.96M | $39.98M | $-225.35M | $6.33M | $7.21M | $49.23M | $381.00K | $-5.00M | $-8.50M | $-75.00K | $-1.00K | $-62.21M | $-165.00K | $-4.20M | $-21.00M | $2.33M | $-300.00K | $-9.90M |
| Net Cash Used for Investing Activities | $-52.91M | $-30.25M | $33.94M | $-67.62M | $-240.66M | $-10.76M | $-8.71M | $-76.22M | $-139.91M | $313.89M | $142.79M | $-147.42M | $-413.40M | $-88.27M | $157.02M | $71.35M | $-97.89M | $-10.09M | $-441.23M | $113.69M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $-777.00K | $254.78M | $- | $- | $250.00M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $108.04M | $132.78M | $25.86M | $30.89M | $24.80M | $49.39M | $27.12M | $259.36M | $153.02M | $22.50M | $27.12M | $246.27M | $72.39M | $81.86M | $46.98M | $100.99M | $- | $99.50M | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $31.00M | $-5.28M | $131.50M | $28.91M | $39.23M | $33.14M | $53.39M | $46.37M | $64.21M | $42.24M | $30.34M | $34.96M | $42.29M | $573.84M | $329.81M | $51.18M | $217.95M | $34.15M | $589.51M | $53.87M |
| Net Cash Used Provided by Financing Activities | $31.00M | $102.75M | $131.50M | $28.91M | $39.23M | $33.14M | $53.39M | $46.37M | $63.44M | $297.02M | $30.34M | $34.96M | $292.29M | $573.84M | $329.81M | $51.18M | $217.95M | $34.15M | $689.01M | $53.87M |
| Effect of Forex Changes on Cash | $-17.27M | $15.09M | $-3.12M | $-9.94M | $10.90M | $-6.55M | $-130.00K | $2.18M | $1.62M | $2.02M | $-8.84M | $-2.24M | $-3.05M | $-3.14M | $1.08M | $-3.91M | $2.97M | $2.14M | $435.00K | $-631.00K |
| Net Change in Cash | $-133.85M | $134.01M | $286.61M | $-130.81M | $-220.34M | $375.23M | $-14.44M | $-194.15M | $-206.83M | $497.65M | $41.48M | $-285.89M | $-274.31M | $348.39M | $366.06M | $-117.04M | $-110.00K | $-84.12M | $112.89M | $-79.23M |
| Cash at End of Period | $968.65M | $1.10B | $968.49M | $681.88M | $812.69M | $1.04B | $659.98M | $674.41M | $868.56M | $1.08B | $577.74M | $536.26M | $822.15M | $1.10B | $748.07M | $382.00M | $499.05M | $499.16M | $583.28M | $470.39M |
| Cash at Beginning of Period | $1.10B | $968.49M | $681.88M | $812.69M | $1.03B | $659.98M | $674.41M | $868.56M | $1.08B | $577.74M | $536.26M | $822.15M | $1.10B | $748.07M | $382.00M | $499.05M | $499.16M | $583.28M | $470.39M | $549.63M |
| Operating Cash Flow | $-94.66M | $43.71M | $124.16M | $-81.52M | $-29.80M | $359.41M | $-58.99M | $-166.47M | $-131.98M | $-115.28M | $-122.82M | $-171.19M | $-150.14M | $-134.04M | $-121.86M | $-235.66M | $-123.14M | $-110.33M | $-135.33M | $-246.16M |
| Capital Expenditure | $-9.09M | $-4.19M | $-8.02M | $-12.97M | $-15.31M | $-17.09M | $-15.92M | $-13.89M | $-21.64M | $-16.51M | $-16.05M | $-17.86M | $-21.89M | $-26.06M | $-11.25M | $-17.18M | $-21.67M | $-12.42M | $-16.66M | $-19.62M |
| Free Cash Flow | $-103.76M | $39.52M | $116.14M | $-94.49M | $-45.10M | $342.32M | $-74.91M | $-180.37M | $-153.61M | $-131.79M | $-138.87M | $-189.05M | $-172.03M | $-160.10M | $-133.10M | $-252.84M | $-144.81M | $-122.74M | $-151.99M | $-265.78M |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
$257.19
Stock Price
$33.45B
Market Cap
2.23K
Employees
Cambridge, MA
Location
Revenue (FY 2024)
$2.25B
23.0% YoY
Net Income (FY 2024)
$-278.16M
36.8% YoY
EPS (FY 2024)
$-2.16
38.6% YoY
Free Cash Flow (FY 2024)
$-42.59M
-201.5% YoY
Profitability
Gross Margin
85.6%
Net Margin
-12.4%
ROE
-414.6%
ROA
-6.6%
Valuation
P/E Ratio
-108.78
P/S Ratio
13.46
EV/EBITDA
-175.72
Market Cap
$33.45B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-8.31M
-108.0% YoY
Free Cash Flow
$-42.59M
-201.5% YoY
Balance Sheet Summary
Total Assets
$4.24B
10.7% YoY
Total Debt
$1.30B
51.7% YoY
Shareholder Equity
$67.09M
129.5% YoY
Dividend Overview
No Dividend Data
Alnylam Pharmaceuticals, Inc. doesn't currently pay dividends.
Alnylam Pharmaceuticals Dividends
Explore Alnylam Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Alnylam Pharmaceuticals News
Read the latest news about Alnylam Pharmaceuticals, including recent articles, headlines, and updates.
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly.
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the.
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois.
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.
siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials
Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering.
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside.
Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps
The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failu.
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18, 2025 at 3:00 pm ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event. About Alnylam Pharm.
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. “Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that.
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day today in New York City and will also webcast the event. The Company plans to showcase its R&D progress and platform innovation, including updates on multiple near- and mid-stage potentially transformative therapies that represent blockbuster opportunities as its pipeline rapidly expands across multiple therapeutic areas. “Alnylam is driving the fi.
Alnylam: Waiting For Regulatory Updates In March
Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows.
Alnylam Delivers a Big Q4 Earnings Beat
Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share.
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO Tolga Tanguler - Chief Commercial Officer Pushkal Garg - CMO Jeff Poulton - CFO Christine Lindenboom - Chief Corporate Communications Officer Conference Call Participants Tazeen Ahmad - Bank of America Kostas Biliouris - BMO Capital Markets Gena Wang - Barclays Maury Raycroft - Jefferies Ritu Baral - TD Cowen Teraesa Vitelli - Scotiabank Gary Nachman - Raymond James Jessica Fye - JPMorgan Paul Matteis - Stifel Salveen Richter - Goldman Sachs Ellie Merle - UBS Mani Foroohar - Leerink Partners Luca Issi - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Fourth Quarter Full Year 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ALNY.